Viking Therapeutics

Woman standing on scales
#Adverse event #Obesity #Phase II trial #Viking Therapeutics #Weight loss

Mixed top-line results for Viking’s oral obesity drug

Viking Therapeutics has released positive top-line results from its Phase II clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.   VK2735 is being developed in both oral and subcutaneous formulations for… Read More

#News #Trending News

Obese man measures his waist
#GlobalData #GLP-1 #Obesity #Phase II trial #Viking Therapeutics #Weight loss

Obesity drug competition expected to intensify by 2030

Viking Therapeutics’ dual GLP-1/GIP receptor agonist VK2735 could become a direct competitor to Eli Lilly’s Mounjaro/Zepbound (tirzepatide), predicts data analytics company GlobalData. In February 2024, Viking Therapeutics published Phase IIa results for its VK2735 candidate, which is being investigated both as a weekly subcutaneous… Read More

#News

#Clinical trial #Obesity #Phase II trial #Trial data #Viking Therapeutics

Positive results for dual GLP-1/GIP receptor agonist in obesity

Viking Therapeutics has reported positive top-line results from the Phase II VENTURE trial of VK2735 in patients with obesity. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The study demonstrated statistically significant reductions in body… Read More

#News